Blood test helps primary care doctors diagnose Alzheimer’s with 90% accuracy, study finds

A blood test measuring Alzheimer's disease biomarkers enabled primary care physicians to diagnose the condition with roughly 90% accuracy — nearly matching specialists — according to new real-world data presented at the Alzheimer's Association International Conference (AAIC) 2026 in London this week.prnewswire+1

Real-World Accuracy Breakthrough

The study, one of the first of its kind, included more than 1,300 patients and 165 physicians across primary and specialty care settings. Before receiving blood test results, primary care physicians correctly diagnosed Alzheimer's in just 65% of cases, while specialists achieved 74% accuracy. After incorporating blood biomarker results measuring amyloid beta and phosphorylated tau, primary care accuracy jumped to 93%, and specialists reached 94%.dementiaresearcher.nihr+1

The findings suggest that a simple blood draw could democratize Alzheimer's diagnosis, removing the bottleneck of specialist referrals that currently delays care for millions of patients. Primary care clinicians changed their diagnoses for 30% of patients after seeing results, with the greatest impact in ruling out Alzheimer's as the cause of cognitive symptoms.dementiaresearcher.nihr

Predicting Disease Years Before Symptoms

The AAIC data builds on a wave of research this year demonstrating the predictive power of blood-based biomarkers. A study published in February in Nature Medicine by Washington University School of Medicine researchers showed that measuring plasma p-tau217 could estimate when Alzheimer's symptoms would begin, with a margin of error of three to four years. Individuals with elevated p-tau217 at age 60 developed symptoms roughly 20 years later.sciencedaily+3

Separately, a UC San Diego study published in March in JAMA Network Open found that the same biomarker predicted dementia risk in women up to 25 years before symptoms appeared. An April study from Mass General Brigham demonstrated that pTau217 levels rose before amyloid PET scans showed any abnormalities, pushing detection even earlier.massgeneralbrigham+2

What It Means for Patients

Two blood tests have now received FDA clearance for clinical use, though they remain approved only for patients already showing cognitive symptoms. The tests are not yet recommended for screening in healthy individuals, and a positive result does not constitute a diagnosis on its own.hopkinsmedicine+3

Still, researchers say the trajectory is clear. "A positive result on these tests does not automatically mean you will exhibit Alzheimer's symptoms, but it certainly indicates a higher risk," said Dr. Suzanne Schindler of Washington University. Some specialists believe such tests will eventually become routine screening tools, comparable to mammograms or colonoscopies.nytimes